Research programme: JNK inhibitors - Eisai
Alternative Names: Compound A; Compound B; ER 181304Latest Information Update: 02 Oct 2021
At a glance
- Originator Eisai Co Ltd
- Class Indoles
- Mechanism of Action JNK mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Multiple-sclerosis in United Kingdom (PO)
- 13 Nov 2010 Pharmacodynamics data from preclinical studies in Multiple sclerosis presented at the 40th Annual Meeting of the Society for Neuroscience (SFN-2010) ,
- 02 Nov 2006 Preclinical trials in Parkinson's disease in Japan (unspecified route)